Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07456605) titled 'Study of the Safety and Usefulness of Liposomal Curcumin in Multiple Myeloma' on March 2.
Study Type: Interventional
Study Design:
Allocation: Non-Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: University Health Network, Toronto
Condition:
Multiple Myeloma Refractory
Multiple Myeloma in Relapse
Intervention:
Drug: Liposomal Curcumin (LipoCurc)
Recruitment Status: Not recruiting
Phase: Phase 1
Date of First Enrollment: March 2, 2026
Target Sample Size: 20
Countries of Recruitment:
Canada
To know more, visit https://clinic...